Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening

JianMin Jia1,2,9, XiaoLi Xu1,2,*, Fang Liu1,2, XiaoKe Guo1,2, MingYe Zhang1,2, MengChen Lu1,2, LiLi Xu1,2, JinLian Wei1,2, Jia Zhu1,2, ShengLie Zhang1,2, ShengMiao Zhang1,2, HaoPeng Sun1,2,3,*, QiDong You1,2,*,

1 State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China, 2 Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China, 3 Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China

Abstract
Heat shock protein 90 (Hsp90), whose inhibitors have shown promising activity in clinical trials, is an attractive anticancer target. In this work, we first explored the significant pharmacophore features needed for Hsp90 inhibitors by generating a 3D-QSAR pharmacophore model. It was then used to virtually screen the SPECS databases, identifying 17 hits. Compound S1 and S13 exhibited the most potent inhibitory activity against Hsp90, with IC50 value 1.61±0.28 μM and 2.83±0.67 μM, respectively. Binding patterns analysis of the two compounds with Hsp90 revealed reasonable interaction modes. Further evaluation showed that the compounds exhibited good anti-proliferative effects against a series of cancer cell lines with high expression level of Hsp90. Meanwhile, S13 induced cell apoptosis in a dose-dependent manner in different cell lines. Based on the consideration of binding affinities, physicochemical properties and toxicities, 24 derivatives of S13 were designed, leading to the more promising compound S40, which deserves further optimization.

Introduction
Heat shock protein 90 (Hsp90), a member of chaperone protein family, which play a crucial role in regulating numerous cellular processes, including protein folding, cell apoptosis, and stress resistance [1–2]. As an ATPase-dependent protein folding molecular chaperone, Hsp90 functions with a cluster of co-chaperones to facilitate the stability and biological function of numerous client proteins, many of which are related to carcinogenesis, such as Met, Erb-B2, VEGF, Akt, EGFR and Bcr-Abl [3–6]. Several Hsp90 clients are notorious oncogenes (Raf-1, Akt, cdk4, Src, Flt-3, H-Tert, c-Met, etc.), and five of them are clinically validated cancer targets: HER-2/neu, Bcr-Abl, estrogen receptor, androgen receptor, and VEGFR [7–10]. Such a major advantage of Hsp90 inhibitors is that they simultaneously attack several pathways which are necessary for cancer development, reducing the likelihood of the tumor acquiring resistance [11]. Additionally, Hsp90 inhibitors have shown selectivity for cancer cells [12–13]. This can be explained for several reasons: (1) the active Hsp90 in cancer cells has higher affinity to Hsp90 inhibitors than the latent form in normal cells, leading to an increased accumulation of inhibitor in cancer cells; (2) Hsp90 is overexpressed in many types of cancers in humans [12–13]. For these reasons, Hsp90 has emerged as a promising target for anti-cancer drug development.

The role of Hsp90 in oncogenic transformation has not been appreciated until the discovery of pharmacological agents that selectively inhibit its function [14–16]. The therapeutic potential of Hsp90 inhibitors has been verified by the initial success of the natural product 17-allylamino-17-demethoxygeldanamycin (17-AAG) in several Phase I and Phase II clinical trials in cancers therapy [17–21]. Additionally, other synthetic Hsp90 inhibitors such as purine derivative BIIB021 and isoxazole derivative VER-52296/NVP-AUY922 also have entered clinical trials [22–25]. Although it has been under clinical trials for many years, 17-AAG encounters a lot of severe problems including poor solubility, liver toxicity and multidrug resistance (MDR) caused by pglycoprotein (P-gp) efflux pump [15,24]. These issues highlight a critical need for novel and improved inhibitors to overcome the limitations.

Computer-assisted techniques, such as pharmacophore-based or docking-based virtual screening has emerged as an effective tool for novel active compound identification. Meanwhile, the crucial information in target-ligand interaction revealed by these methods also has improved the reasonability and accuracy of molecular design. A large number of successful applications in medicinal chemistry have demonstrated the importance of these methods in drug design [25–27].

With the aim of acquiring novel scaffolds of Hsp90 inhibitors, in the present study, a 3D pharmacophore model, Hypol, was generated on the basis of 18 known Hsp90 inhibitors. The model was validated by external dataset containing 30 known Hsp90 inhibitors and then used for virtual screening. Hit compounds from SPECS database were validated by molecular docking and

PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e59315
17 retained compounds were bought and subjected to biological evaluation. Compound S1 and S13 with novel scaffolds exhibited potent Hsp90 inhibitory activity, with IC_{50} 1.61±0.28 μM and 2.83±0.67 μM, respectively. The two compounds also showed good cytotoxicity against a series of cancer cell lines. S13-induced cell morphological change of MCF-7 cancer cells was observed. A panel of the client proteins, including Her2, Src, Akt, ERK, c-Raf and Hif-1α, were also found to be downregulated by S13. Using S13 as lead, 24 novel derivatives were designed and evaluated based on their binding affinities, physicochemical properties and toxicities, leading to a more promising compound S40, which deserves further optimization.

Materials and Methods

General methodology and materials

The following program were used in the manuscript: Discovery Studio 3.0 software package for pharmacophore model generation (DS, Accelrys Inc., San Diego, USA); Gold 5.0 program for molecular docking (CCDC, UK); Derek 2.0.3 for the toxicities prediction (Lhasa Inc., UK); MarvinSketch 5.10.0 for the physicochemical properties prediction (Chemaxon Ltd., USA). All the calculation and display of the molecules were performed on Dawning 560I workstation.

The following materials were used for the biological evaluation: The PET-28a HSP90 expression vector was constructed. The Ni^{2+}-nitrilo-triacetic acid (NTA) agarose was purchased from General Electric (USA). 17-Dimethylamino-ethylamino-17-de-methoxygeldanamycin (17-DMAG) and AT13387 were from Selleck (USA). Isopropyl-1-thio-d-galactopyranoside (IPTG) was purchased from Sigma (St. Louis, MO). Antibodies of β-Actin, Hsp70, Hsp90, c-Raf, Akt, Src, Phospho-Src, ERK and Her-2 were purchased from Cell Signaling Technology (Danvers, MA). Anti-p-Akt(S473) was purchased from Signalway Antibody (Baltimore, MD). HIF-1α antibody was purchased from R&D Systems. The stock solution of Hsp90 was prepared in a 20 mM Tris-Cl buffer with a pH 7.4, and concentration was fixed at 5.0 μM. Hsp70 (human, recombinant, ALX-201-214-C025) with ATPase activity is supplied by Enzo Life science (Waterloo, Australia). The screened out compounds were purchased from SPECS and dissolved in DMSO (Sigma, St. Louis, MO) to make a final concentration of 10^{-7} mol/L and were stored at −20°C. The tumor cells HCT116, HepG2, MDA-MB-231, MCF-7, SKBr3 and A549 were purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Science. The water used in the experiments was thrice-distilled and all other materials were of analytical reagent grade.

Training set and test set selection

In the course of construction of pharmacophore model, the selection of training set will deeply affect the accuracy and reliability of the model. According to literature reported rules [28], the principles for selecting training set are as follows: a) the number of compound in the training set is more than sixteen; b) all the biological data were obtained using similar method, and the data can cover an activity range of at least four orders of magnitude (at least 4 compounds for each order of magnitude); c) the set must contain structurally diverse compounds to ensure that each compound can provide new features to the pharmacophore model. In this study, the activity data for training set and test set molecules were obtained from several literatures [23,29,30]. According to the above rules, eighteen compounds (No. 1–18 in Figure 1), with IC_{50} ranging from 0.006 μM to 31.5 μM, were used as training set to generate HypoGen hypotheses. Another thirty Hsp90 inhibitors with diverse activities and structures were selected as test set to validate the pharmacophore model (No. 19–48 in Figure 2). The biological data (represented as IC_{50} values) of these inhibitors were determined under a similar experimental condition by using a fluorescence polarization (FP) competitive binding assay method [23,29,30]. All molecules were built using
Prepare Ligands module and Minimize Ligands module in DS. Multiple conformations of each compound were generated by using Diverse Conformation Generation protocol with an energy threshold of 20 kcal/mol and a maximum of 255 conformers.

Generation of pharmacophore hypotheses with 3D-QSAR pharmacophore generation (HypoGen)

HypoGen attempts to develop SAR hypothesis models from a set of molecules for which activities (IC_{50}, K_{i}, etc.) on a given biological target have been measured. Based on the chemical features of compounds in the training set, we selected the following chemical functions in the feature dictionary: hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), hydrophobic (HY), and hydrophobic aromatic (HYAr) groups. A default uncertainty factor of 3 for each compound was then defined for the representation of the ratio range of uncertainty in the activity value based on the expected statistical straggling of biological data collection. Pharmacophore models were then generated by using 3D-QSAR Pharmacophore Generation protocol, and the top ten unique pharmacophore models were finally exported.

Validation of Pharmacophore Model

The quality of 3D-QSAR pharmacophore models can be best described in terms of two cost-related parameters provided by Catalyst program. The first one is the cost of an ideal hypothesis, which is a lower bound on the cost of the simplest possible hypothesis that still fits the data perfectly; the second one is the cost of the null hypothesis, which presumes that statistically significant structure was not included in the data. For a reliable pharmacophore model, the total cost should be close to the fixed cost, and there should be a significant difference between null and total cost. Further, a value of 40–60 bits for the unit of cost difference implies

---

Figure 2. 2D chemical structures of 30 test set molecules for the pharmacophore model validation.

doi:10.1371/journal.pone.0059315.g002
a 75–90% probability of the correlation between experimental and predicted activities [28].

To verify if the hypothesis can also predict the activity of external compounds, a test set consisting of other 30 molecules (No. 19–48 in Figure 2) in different activity and structural classes were applied to examine the established hypothesis by using the same way as in the training set. All test set molecules were built and minimized as the training set molecules. For further evaluation of the quality of the generated Pharmacophore model, we selected the crystal structure of Hsp90-ligand complex (id: 2vcj) from the Protein Data Bank (PDB). The crystal conformation of the ligand were extracted from the complex and then overlapped onto the pharmacophore model by using the Láncs Pharmacophore Mapping protocol implemented in the Discovery Studio package.

**Database searching**

Virtual screening of commercial available databases forms one aspect of an efficiently approach to find novel and potential leads for further development [31]. In this study, the best-ranked four-

**Table 1. Results of pharmacophore hypotheses generated by HypoGen.**

| Hypo | Total cost | Cost diff. | rms deviation | Correlation (r) | Features |
|------|------------|------------|---------------|-----------------|----------|
| Hypo1 | 79.556 | 103.179 | 1.054 | 0.961 | HBA, HBA, HBD, HY |
| Hypo2 | 80.008 | 102.727 | 1.076 | 0.960 | HBA, HBA, HBD, HY |
| Hypo3 | 86.764 | 95.971 | 1.289 | 0.942 | HBA, HBA, HBD, HY |
| Hypo4 | 96.923 | 85.812 | 1.731 | 0.891 | HBA, HBA, HBD, HY |
| Hypo5 | 97.842 | 84.893 | 1.755 | 0.888 | HBA, HBD, HY, HY |
| Hypo6 | 97.856 | 84.879 | 1.770 | 0.885 | HBA, HBD, HY, HY |
| Hypo7 | 97.994 | 84.741 | 1.777 | 0.884 | HBA, HBD, HY, HY |
| Hypo8 | 98.479 | 84.256 | 1.742 | 0.890 | HBA, HBD, HY, HY |
| Hypo9 | 99.674 | 83.061 | 1.830 | 0.877 | HBA, HBD, HY, HY |
| Hypo10 | 100.890 | 81.846 | 1.843 | 0.875 | HBA, HBD, HY, HY |

*Number for the hypothesis are consistent with the numeration as obtained as obtained by the hypothesis generation.

Cost difference between the null cost and the total cost, the null cost of the 10 top-scored hypotheses is 182.735, the fixed cost value is 69.5474, and the configuration cost is equal to 16.1676.

*Pharmacophore features were encoded by HBA for hydrogen bond acceptor, HBD for hydrogen bond donor and HY for hydrophobic features.

doi:10.1371/journal.pone.0059315.t001

![Figure 3. Top scoring pharmacophore model Hypo1 of Hsp90 inhibitors.](https://example.com)
Table 2. The actual IC50 value and estimate value predicted by Hypo1 in the training set.

| Compd. no. | Fit IC50 (nM) | Errorsa |
|------------|--------------|---------|
| 1          | 7.68         | 2.4     | 6       | −2.5  |
| 2          | 6.32         | 55      | 29      | +1.9  |
| 3          | 6.43         | 43      | 37      | +1.2  |
| 4          | 6.51         | 35      | 39      | −1.1  |
| 5          | 5.70         | 230     | 40      | +5.7  |
| 6          | 6.54         | 33      | 56      | −1.7  |
| 7          | 5.38         | 470     | 200     | +2.4  |
| 8          | 5.66         | 250     | 230     | +1.1  |
| 9          | 5.41         | 440     | 280     | +1.6  |
| 10         | 4.99         | 1200    | 700     | +1.7  |
| 11         | 4.39         | 4700    | 4700    | −1    |
| 12         | 4.59         | 2900    | 4800    | −1.6  |
| 13         | 4.70         | 2300    | 6100    | −2.7  |
| 14         | 4.46         | 3900    | 6600    | −1.7  |
| 15         | 4.59         | 2900    | 7100    | −2.4  |
| 16         | 3.79         | 18000   | 15000   | +1.2  |
| 17         | 3.42         | 43000   | 20000   | +2.2  |
| 18         | 3.97         | 12000   | 31000   | −2.6  |

*Value in the error column represents the ratio of the estimated activity to the tested activity or its negative inverse if the ratio is lower the one.

doi:10.1371/journal.pone.0059315.t002

Physicochemical properties and toxicities prediction of the designed compounds

The physicochemical properties including CLogP, polar surface area (PSA) of the compounds were calculated by Chemaxon MarvinSketch 5.10.0. Weighted method was used and all the parameters were set as default. The toxicities of the compounds were predicted by using Derek 2.0.3. All the endpoints in mammal were selected for prediction and the data were saved as PDF format.

Anti-proliferation activity

Cell viabilities were measured by a colorimetric assay using 3-(4, 5-dimethylthiazol-2-y1)-2,5-diphenyltetrazoliumbromide (MTT, Sigma, Ltd) as described previously. Experiments were carried out in triplicate in a parallel manner for each concentration of target compounds and the results were presented as mean ± SE. Control cells were given only culture media. After incubation for 48 h, absorbance (A) was measured at 570 nm. Survival ratio (%) was calculated using the following equation: survival ratio (%) = (A<sub>treatment</sub>/A<sub>control</sub>) × 100%. IC50 was taken as the concentration that caused 50% inhibition of cell viabilities and calculated by the SAS statistical software.

Cell morphological assessment

To detect morphological evidence of apoptosis, HCT116, MCF-7 and SKBR3 cell nuclei were visualized following DNA staining with the fluorescent dye DAPI. Briefly, cells were seeded at a concentration of 1×10<sup>5</sup> cells/well in 6-well tissue culture plates and treated with indicated concentration of S13. At the end of incubation, the morphology of cells was monitored under an inverted light microscope. Cells were then fixed with 4% paraform for 20 min and washed with PBS, and then incubated with DAPI (1 µg/ml) for 10 min. After washed with PBS, cells were observed...
using fluorescent microscopy (Olympus, Japan) with a peak excitation wave length of 340 nm.

**The preparation of Hsp90**

The region encoding full-length Hsp90 was subcloned into pET28a. Protein expression in E. coli cells were induced with 0.5 mM IPTG. Cells were harvested after 20h of growth at 16°C and then disrupted by sonication. The soluble lysate was clarified by centrifugation and applied to a Ni²⁺-nitro-triacetic acid (NTA) agarose column in a buffer (50 mM Tris-Cl, 300 mM NaCl, 10 mM Imidazole, 10% [v/v] Glycerol, 10 mM PMSF, 10 mM DTT). Hsp90 Protein was eluted with a linear gradient of 20–1000 mM imidazole. Hsp90 was identified by SDS-PAGE, and the high concentrated fraction was dialyzed against ATPase buffer (20 mM Tris-Cl, pH 7.5; 6 mM MgCl₂; 20 mM KCl) and then aliquoted, frozen in liquid nitrogen, stored at -280°C.

The test compounds were diluted from mother plates (10 mM in 100% (v/v) DMSO) into daughter plates (200 μM in 2.0% (v/v) DMSO); 5 μL of test compound solution was added to each well (equivalent to a final concentration of 40 μM) of the 96-well assay plate. The first and last rows of the 96-well plate contained the appropriate concentration of DMSO were used as blank control. ATP was dissolved in the assay buffer to give a stock concentration of 2.5 mM and stored at room temperature. A 10 μL aliquot of ATP solution was added to each well to give a final assay concentration of 1 mM. Before the usage, Hsp90 protein was thawed on ice and suspended in chilled assay buffer to a stock concentration of 0.35 mg/mL, and the solution was kept on ice. The incubation was started by adding 10 μL of the stock Hsp90 to each well (except for the background wells which received 10 μL of assay buffer), giving a final assay volume of 25 μL. The plates were shaken for approximately 2 min and incubated for 3 h at 37°C.

Two methods are used to evaluate the Hsp90 ATPase activity by detecting HSP90 phosphorylation level.

**Malachite Green Assay**

The assay procedures were based on the literatures [33–35]. The malachite green reagent was prepared and contained malachite green (0.0812%, w/v), polyvinyl alcohol (2.32%, w/v; dissolves with difficulty and requires heating), ammonium molybdate (5.72%, w/v, in 6M HCl), and AR water, mixed in the ratio 2:1:1:2. The reagent is initially dark brown, but on standing for ~2 h at room temperature changes to a golden yellow and is ready for use. The assay buffer was 100 mM Tris–HCl, 20 mM KCl, 6 mM MgCl₂, pH 7.4.

To stop the ATPase reactions, 80 μL of the malachite green reagent was added to each well. Following the addition of 10 μL of 34% sodium citrate to each well, the plate was incubated at room temperature for about 15 min, and the absorbance at 620 nm was measured by Varioskan multimode microplate spectrophotometer (Thermo, Waltham, MA, USA).

**ATP Hydrolysis Inhibition**

The Discover RX ADP Hunter™ Plus Assay kit (Discoverx, Fremont, CA) was used following the manufacturer’s instructions. ATPase reactions were carried out after 3 h at 37°C temperature in presence of different concentrations of compounds. ADP generation was measured using Varioskan multimode microplate spectrophotometer (540 nm excitation and 620 nm emission). Fluorescence intensity values measured for Hsp90 without any testing compound was assumed as 100% of enzyme activity. The background reaction rate was measured in a reaction lacking enzyme or substrate and subtracted from the experimental rates.

**Hsp70 ATPase activity assay**

Hsp70 ATPase activity was measured using Discover RX ADP Hunter™ Plus Assay kit as described in the manufacturer's instructions. Briefly, Hsp70 (3 μM) was incubated with 1 mM ATP in 100 mM Tris pH 7.4 at 37°C for 3 h in the presence or absence of various concentrations of test compounds. ADP generation was measured using Varioskan multimode microplate spectrophotometer (540 nm excitation and 620 nm emission). Fluorescence intensity values measured for Hsp70 without any testing compound was assumed as 100% of enzyme activity. The background reaction rate was measured in a reaction lacking enzyme or substrate and subtracted from the experimental rates.

![Figure 5. The regression of actual versus predicted activities in the training and test set molecules.](doi:10.1371/journal.pone.0059315.g005)
Western-Blot analysis

MCF-7 cells were pretreated with various concentrations of the test compounds. After stimulation, cells were collected, lysed in lysis buffer [50 mM Tris–Cl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Nonidet P-40 (NP-40), 0.2 mM Phenylmethanesulfonyl fluoride (PMSF), 0.1 mM NaF and 1.0 mM dithiothreitol (DTT)], and the supernatant was obtained after centrifugation at 13,000g for 10 min at 4°C. The concentration of protein in the supernatants was measured by the bicinchoninic acid (BCA) assay. Then equal amounts of protein (50 μg) were separated by 8% or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto the PVDF membranes (Millipore, Billerica, MA). The blots were incubated with specific antibodies against the indicated primary antibodies overnight at 4°C followed by IRDyeTM800-conjugated secondary antibody for 1 h at 37°C. Detection was performed by the Odyssey Infrared Imaging System (LI-COR; Lincoln, NE). All blots were stripped and incubated with polyclonal anti-β-actin antibody to ascertain equal loading of proteins.

Table 3. Actual and estimated activities in the test set.

| Compd. no. | Fit | IC50 (nM) | Activity* scale | Errors |
|------------|-----|-----------|-----------------|--------|
|             | Estimate | Actual | Activity scale |
| 19          | 7.74  | 2.1       | +++ 6           | −2.9   |
| 20          | 7.623 | 2.7       | +++ 14          | −5.2   |
| 21          | 7.222 | 6.8       | +++ 8           | −1.2   |
| 22          | 6.893 | 14.7      | +++ 20          | −1.4   |
| 23          | 6.543 | 32.9      | +++ 64          | −2.0   |
| 24          | 6.539 | 33.2      | +++ 87          | −2.6   |
| 25          | 6.535 | 33.5      | +++ 39          | −1.2   |
| 26          | 6.517 | 34.8      | +++ 102         | −2.9   |
| 27          | 6.509 | 35.6      | +++ 127         | −3.6   |
| 28          | 6.503 | 36.0      | +++ 80          | −2.2   |
| 29          | 6.459 | 40.0      | +++ 37          | 1.1    |
| 30          | 6.403 | 45.4      | +++ 47          | −1.0   |
| 31          | 6.331 | 53.6      | +++ 142         | −2.6   |
| 32          | 6.272 | 61.3      | +++ 84          | −1.3   |
| 33          | 6.263 | 62.7      | +++ 58          | 1.1    |
| 34          | 6.151 | 81.1      | +++ 58          | 1.4    |
| 35          | 5.637 | 264.8     | ++ 720          | −2.7   |
| 36          | 5.407 | 449.7     | ++ 340          | 1.3    |
| 37          | 5.37  | 489.6     | ++ 431          | 1.1    |
| 38          | 5.355 | 507.3     | ++ 914          | −1.8   |
| 39          | 4.824 | 1720.5    | ++ 1300         | 1.3    |
| 40          | 4.444 | 4132.1    | ++ 2200         | 1.9    |
| 41          | 4.207 | 7122.1    | ++ 6100         | 1.2    |
| 42          | 4.171 | 7741      | ++ 13900        | −1.8   |
| 43          | 4.097 | 9178.5    | ++ 10700        | −1.2   |
| 44          | 4.073 | 9700.9    | ++ 9100         | 1.1    |
| 45          | 4.025 | 10848.9   | + 10500         | 1.0    |
| 46          | 3.749 | 20456.8   | + 22300         | −1.1   |
| 47          | 3.417 | 43945.6   | + 47600         | −1.1   |
| 48          | 3.324 | 54632.7   | + 56500         | −1.1   |

*Activity scale: high active (<100 nM, +++); moderately active (100–10000 nM, ++) and inactive (>10000 nM, +).

doi:10.1371/journal.pone.0059315.t003

Figure 6. The congruent map of the ligand 2EQ with different conformation. The actual conformation of the ligand 2EQ in the Hsp90 protein crystal complex was shown as red sticks and the active conformation predicted by Hypo1 was shown as green sticks. doi:10.1371/journal.pone.0059315.g006

Figure 7. The pharmacophore Hypo1 mapped into the binding site of Hsp90 protein. Ligand and the key residues were shown as stick form and the hypothesis features were color-coded as figure 3. doi:10.1371/journal.pone.0059315.g007
hydrogen donor, hydrogen acceptors and hydrophobic center (Table 1).

The top-ranked one, Hypo1 (Figure 3), consists of two hydrogen bond acceptors, one hydrogen donor, and one hydrophobic features. In details, the null cost value of the best 10 ranking hypothesis is 182.735, and the fixed cost value is 69.5474. Configuration cost, a constant value less than 17, describing the complexity of the hypotheses space to explore, is 16.1676. As the best model, Hypo1 is characterized by the highest cost difference (79.556), the lowest rms deviation value (1.045) and the best correlation coefficient value (0.961), which represents a true correlation and a good predictability of Hypo1. As a result, it was retained for further analysis.

In addition to the cost analysis, another validation method is to check for Hypo1’s capacity to correctly predict the activity of the training set compounds. Except compound 5, the predicted errors of all the training set compounds were less than 3 (Table 2), indicating that most of the IC50 values were predicted correctly.

Then the most active compound 1 and the very low active compound 17 were mapped onto Hypo1, respectively. Compound 1 fitted all features of Hypo1 very well (Figure 4A). The hydrophobic feature was mapped by the phenyl group, the two hydrogen acceptor features were fitted by the oxygen atom of a phenolic group and imidazole ring, respectively, and the hydrogen donor feature was located on the hydrogen atom of amide. While for the case of compound 17 (Figure 4B), a hydrophobic feature overlapped with the phenyl rings, and the amine served as the hydrogen donor, whereas the two hydrogen features mapping were missing, leading to the dramatically decrease in activity.

Finally, we applied a test set of 30 molecules with diverse chemical structures (Figure 2) to verify the prediction accuracy of Hypo1. The test set molecules were mapped onto Hypo1 and the actual activity versus estimated activity were calculated (Table 3), and most of members of test set were correctly predicted. We also used Hypo1 to perform a regression analysis with the test set compounds in order to check the predictive ability of this model. Linear regression of the predicted activities versus the experimental ones gave a fairly good correlation coefficient of 0.984 (Figure 5), confirming the prediction accuracy of our model.
Evaluating the fit of the pharmacophore to the binding site of the crystal complex of Hsp90 with ligand

We also attempted to evaluate the correlation between of the Hypo1 predicted conformation and the originally bound conformation of a potent Hsp90 ligand. The conformation of the ligand 2EQ (PDB ID: 2vcj) that fitted (Map Ligands to Pharmacophore protocol, ‘best fit’ option) to Hypo1 was compared to the originally bound conformation (Figure 6). The two conformations shared a very similar manner, with the root mean square distance (RMSD) of the heavy atom 0.93 Å. The data indicates the prediction accuracy of Hypo1 in generating the active conformation of potent compounds.

Additionally, we implemented the pharmacophore model into the active site of Hsp90 crystal structure (PDB id: 2vcj, Figure 7). The pharmacophore Hypo1 is in good agreement with the target-based pharmacophore. Hypo1 appears to accommodate into a narrow tubular pocket of the active site. In the Hsp90 protein crystal structure, the hydrophobic feature of the Hypo1 was located in a hydrophobic cavity formed by residues Gly108, Thr109 and Ile110. The hydrogen bond donor feature pointed to Asp93 and the two acceptor features point to Gly97 and Thr184. Overall, these observations confirm that the proposed ligand-

Table 4. Inhibition of Hsp90 of selected 17 compounds.

| Compd. | SPECS ID      | Inhibition rate (% in 40 μM) | Hsp90 IC₅₀ (μM)     | Fit Value | Docking Score |
|--------|---------------|-------------------------------|---------------------|-----------|---------------|
| S1     | AP-124/43237941 | 69.71                         | 2.44±0.33* 1.61±0.28b | 7.97      | 37.08         |
| S2     | AG-205/37107115 | −10.22                        | ND                  | 7.05      | 19.94         |
| S3     | AN-465/41674426 | −11.55                        | ND                  | 7.15      | 24.67         |
| S4     | AF-399/418999907 | 48.22                        | ND                  | 7.63      | 34.24         |
| S5     | AF-399/42099910 | −14.46                        | ND                  | 7.08      | 15.84         |
| S6     | AF-399/42047618 | −7.53                         | ND                  | 7.11      | 14.51         |
| S7     | AG-690/13779041 | −35.07                        | ND                  | 7.01      | 9.48          |
| S8     | AJ-292/11386001 | 47.77                         | ND                  | 7.07      | 38.89         |
| S9     | AP-906/42087482 | −47.83                        | ND                  | 7.03      | 17.16         |
| S10    | AP-906/42087889 | 36.04                         | ND                  | 7.55      | 38.78         |
| S11    | AP-906/42087549 | 42.79                         | ND                  | 7.22      | 37.05         |
| S12    | AH-487/41949127 | 12.57                         | ND                  | 7.17      | 32.33         |
| S13    | AF-399/42611344 | 70.58                         | 3.89±0.54* 2.83±0.67b | 8.06      | 35.98         |
| S14    | AP-124/43383126 | 47.53                         | ND                  | 7.79      | 34.89         |
| S15    | AG-670/36820009 | 18.88                         | ND                  | 7.04      | 24.61         |
| S16    | AO-638/40907376 | −6.22                         | ND                  | 7.10      | 18.71         |
| S17    | AA-504/21163113 | 48.78                         | ND                  | 7.86      | 33.50         |
| 17-DMAG |                | 90%                           | ND                  | ND        | ND            |

*by malachite green assay.
†by ADP fluorescence assay.
doi:10.1371/journal.pone.0059315.t004

Evaluating the fit of the pharmacophore to the binding site of the crystal complex of Hsp90 with ligand

We also attempted to evaluate the correlation between of the Hypo1 predicted conformation and the originally bound conformation of a potent Hsp90 ligand. The conformation of the ligand 2EQ (PDB ID: 2vcj) that fitted (Map Ligands to Pharmacophore protocol, ‘best fit’ option) to Hypo1 was compared to the originally bound conformation (Figure 6). The two conformations shared a very similar manner, with the root mean square distance (RMSD) of the heavy atom 0.93 Å. The data indicates the prediction accuracy of Hypo1 in generating the active conformation of potent compounds.

Additionally, we implemented the pharmacophore model into the active site of Hsp90 crystal structure (PDB id: 2vcj, Figure 7). The pharmacophore Hypo1 is in good agreement with the target-based pharmacophore. Hypo1 appears to accommodate into a narrow tubular pocket of the active site. In the Hsp90 protein crystal structure, the hydrophobic feature of the Hypo1 was located in a hydrophobic cavity formed by residues Gly108, Thr109 and Ile110. The hydrogen bond donor feature pointed to Asp93 and the two acceptor features point to Gly97 and Thr184. Overall, these observations confirm that the proposed ligand-

![Figure 10.](image-url)
based pharmacophore model can fit into the binding pocket and matches well with the topology of the active site.

Database screening for potential Hsp90 inhibitors

To identify novel Hsp90 inhibitors, we built a screening protocol (Figure 8), containing a series of filters, to carry out the virtual screening using Hypo1. SPECS database containing 263,148 compounds was searched using the ‘3D database searching’ protocol in DS. 16120 compounds mapped all critical features in Hypo1 were found and 3210 of them with fit value over 7.0 were retained further analysis. Then an additional filter based on the Lipinski’s rule of five was applied for selecting the druggable compounds. After the filtering, we got 673 compounds for further docking studies.

According to the experimental section, the crystal structure 3d0b was used to perform the docking study using Gold 5.0. Totally, the top-score 43 compounds with reasonable binding conformations were retained and analyzed carefully to avoid similar structures. Finally, 17 compounds were selected and purchased from SPECS for biological test (Figure 9).

Biological assay of the hit compounds

To characterize the inhibition of Hsp90 by the 17 compounds, a colorimetric assay for inorganic phosphate was used to measure the ATPase activity of Hsp90. Several compounds (S4, S8, S11, S14, S17) exhibited moderate Hsp90 inhibition activity. The most potent compounds, S1 and S13, whose inhibition rate were over 50%, were further tested for their IC50 (Table 4). The data showed that the two compounds exhibited a dose-dependent manner, with IC50 2.44 ± 0.33 μM and 3.89 ± 0.54 μM. 17-DMAG and AT13387 were used as positive controls, with IC50 0.95 ± 0.11 μM and 0.37 ± 0.05 μM, respectively.

To confirm the results of malachite green assay, we performed another assay using different method. The Discover RX ADP Hunter™ Plus Assay kit was used for the bioevaluation. The data showed that S1 and S13 inhibited Hsp90 with IC50 1.61 ± 0.28 μM and 2.83 ± 0.67 μM. The results confirmed the inhibitory effects of our compounds on Hsp90 (Figure 10).

To evaluate the inhibitory selectivity of our compounds on different kinds of ATPase, we next tested the activities of S1 and S13 on the non-GHKL ATPase Hsp70 based on the Discover RX ADP Hunter™ Plus Assay kit. S1 showed inhibitory IC50 28.20 ± 2.27 μM and S13 shows inhibitory IC50 43.83 ± 4.38 μM on HSP70 (Figure 10). Both the two compounds inhibit HSP90 over 15 times more potent than HSP70, indicating a target selectivity character of the compounds. Although the selectivity is lower than the positive control AT13387 (IC50 16.30 ± 1.20 μM)

**Figure 11.** The binding mode analysis of compound S1 and S13 with Hsp90 and pharmacophore model Hypo1. A and C, S1 and S13 binding to the active site of Hsp90, respectively. B and D, S1 and S13 mapped onto the pharmacophore model Hypo1, respectively. S1, S13 and the key residues were shown as stick. H-bond was colored in red. Hypothesis features are color-coded as follows: hydrophobic aromatic, light blue; hydrogen bond donor, violet; hydrogen bond acceptor, green.

doi:10.1371/journal.pone.0059315.g011

**Table 5.** Anticancer activity data of S1 and S13 (IC50 values in μM).

| Compd. | SK-BR-3 | A549 | HCT116 | HepG2 | MDA-MB-231 | MCF-7 |
|--------|---------|------|--------|-------|-------------|-------|
| S1     | 15.75   | 25.88| 4.66   | 2.27  | 2.27        | 3.79  |
| S13    | 3.32    | 0.83 | 3.63   | 96.56 | 14.64       | 2.01  |
| 17-DMAG| 1.21    | 0.057| 0.26   | 0.49  | 0.048       | 0.037 |

doi:10.1371/journal.pone.0059315.t005
and 0.34±0.08 µM on HSP70 and Hsp90, respectively, over 47 times more selective than Hsp70, the two compounds show similar manner with AT13387.

Compared to Hsp90, the ATP binding site of Hsp70 has a more polar nature, which requires polar chemical groups in the inhibitor, such as carboxyl group or quaternary ammonium, for the inter-molecular recognition [36]. However, for our compounds, there are no these groups, making the molecules unsuitable to bind with HSP70. This chemical nature of our compounds can also explain the selectivity of our compounds.

The binding modes of S1 and S13 to the active site of Hsp90 as well as the Hypol were carefully analyzed. For S1, naphthalene ring was surrounded by hydrophobic residues Phe138, Tyr139, Val150 and Trp152, the oxygen atom in sulfonamide formed H-bond with Lys58 (Figure 11A). While mapped onto Hypol, the piperazine ring and the oxygen atom in sulfonamide served as H-bond acceptor, the hydroxyl group was recognized as H-bond donor, and the bromine atom was located on the hydrophobic center (Figure 11B). For S13, the hydroxyl group served as H-bond donor, the phenoxy and ethoxy acted as the H-bond acceptor, while the 2-methoxyphenyl ring occupies the hydrophobic center (Figure 11D). While binding to Hsp90 (Figure 11C), the whole scaffold of the molecule inserted well into the binding pocket. The hydroxyl group formed H-bond with Gly135, and the oxygen atom in phenoxy formed another H-bond with Tyr139. The binding modes analysis indicates that S1 and S13 can fulfill the requirement of Hsp90 inhibitor in not only structure-based manner but also ligand-based manner, this explains the activities of the compounds.

Figure 12. Morphologic changes of the whole cancer cells (A–D) and the nuclei (E–H) induced by compound S13. Cultured HCT116, MCF-7 and SkBR3 cells were treated with compound S13 at the indicated concentrations. The cells were then were stained with DAPI and observed by fluorescence microscopy, as described in Experimental section. A, 2.0 µM of S13; B, 5.0 µM of S13; C, 10.0 µM of S13; D, Control group; E, 2.0 µM of S13; F, 5.0 µM of S13; G, 10.0 µM of S13; H, Control group.

doi:10.1371/journal.pone.0059315.g012
S1 and S13 were further tested for their cytotoxicity against a series of cancer cell lines including SKBR3, A549, HCT116, HepG2, MCF-7 and SK-BR3 cells, such as distortion, membrane blebbing and shrinkage, and a large proportion of cells became round in shape and necrosis at high concentrations, while cells in untreated group grew well and their cytoskeletons were clear (Figure 12). The fluorescence microscopic analysis (×200) presented significant morphological changes of early apoptosis when treated with S13. Being identified by DAPI staining, the bright nuclear condensation and the apoptotic bodies appeared after treatment with S13, while the untreated cells displayed normal shape and clear skeleton (Figure 12). From the quantification we can observe the dose-dependent apoptosis-induced effects of S13 in all the tested cell lines, and over 50% of apoptosis is induced by 10 μM S13 in MCF-7 cells (Figure 12). The results confirm the inhibitory effect of our discovered compounds against Hsp90 on a cell-based level, indicating them as promising leads for novel anti-cancer agents.

To further characterize S13 as a potential Hsp90 inhibitor, MCF-7 cells were treated with varying concentrations of S13 for 36 h, and equivalent amounts of protein from cell extracts were Western blotted for Hsp90, Hsp70 and a series of client proteins of Hsp90, including Her2, Src, Akt, ERK, c-Raf and Hif-1α, using β-actin as a loading control, and DMSO as a negative control. S13 was observed to deplete MCF-7 cells of the Hsp90-dependent client proteins in a concentration-dependent fashion (Figure 13), which was in a similar manner with the IC50 value for inhibition of the proliferation of the cell line induced by S13. Meanwhile, S13 dose-dependently up-regulates Hsp70. These data all confirm that S13 inhibits the activity of Hsp90, leading to the misfolding of the

Figure 13. Western-Blot analysis of the expression level of Hsp90, Hsp70 and several client proteins of Hsp90 after incubation with S13 in MCF-7 cells. S13 was incubated with MCF-7 cancer cells at concentrations (μM) for 36 h indicated in the figure. S13 was evaluated for its ability to downregulate the client protein as described in the Experimental Section. Cell extracts were prepared and equivalent amounts of protein were separated by SDS-PAGE and subsequently western-blotted for the indicated proteins.

doi:10.1371/journal.pone.0059315.g013

S1 and S13 were further tested for their cytotoxicity against a series of cancer cell lines including SKBR3, A549, HCT116, HepG2, MCF-7 and MDA-MB-231 (Table 5). The results showed that the two compounds, especially S13, showed potent and dose-dependent proliferation inhibition on SKBR3, MCF-7, A549 and HCT116 cells with high Hsp90 expression level.

Figure 14. The binding patterns of compound S13 (A), S27 (B), S31 (C) and S40 (D) in the active site of Hsp90.

doi:10.1371/journal.pone.0059315.g014
client proteins, which finally degraded by ubiquitin-proteasome pathway. The results further support the enzyme-based and cell-based evaluation data and indicate that the anti-proliferative effect of S13 on cancer cell growth is mediated, at least in part, by its ability to inhibit Hsp90.

**Design of new derivatives based on lead compound S13**

In order to obtain more potent compounds with improved druggability, compound S13 was chosen as lead for further molecular modification.

Although S13 bind well to Hsp90, it only occupied part of the binding site, missing the occupation of the hydrophobic sub-pocket P1 (Figure 14A). To solve this problem, we tried to change the methoxy on the phenyl ring with different kinds of substituents, including steric, electron-withdrawing and electron-donating group, leading to the first series of compounds (ranging from S18–S29, first series in Figure 15). The docking scores of the compounds indicated that the steric groups obviously enhanced the binding abilities (S20, S27–S29), while neither electron-withdrawing nor electron-donating groups affected the docking score. The enhanced dock score can be explained by the extra occupation of the P1 sub-pocket (Figure 14B). Although S28 showed the best score, it exhibited too high CLogP (Table 6), this reduced its druggability and might hinder the further development of the compound. As a result, S27 with the second best score in the first series of compounds were selected as lead for the next modification.

We then explored the significance of the hydroxyl group of S13. Although it served as the H-bond donor, we thought it may be easily oxidized in vivo, making the molecule unstable in metabolism. Therefore, the second series of compounds with other kinds of groups substituting the hydroxyl were designed (S30–S33, second series in Figure 15). The docking score of the four compounds decreased a little compared to S27. Meanwhile, the CLogP increased obviously, which may lead to the poor permeability and absorption of the compounds. While binding to Hsp90 (Figure 14B), the hydroxyl oriented to the polar region of the active site, forming H-bond with Gly135, however, this polar contact was missing when compound S31 bind to Hsp90 (Figure 14C), lowering the binding affinity. All these data proved the significance of the hydroxyl group.

While docking S27 to Hsp90, we found it missing another polar sub-pocket (P2, Figure 14C) adjacent to the main pocket. With the

---

**Table 6. The physicochemical properties and toxicity prediction of the designed compounds.**

| Compd. ID | Chemscore | CLogP | PSA  | Toxicity*a |
|-----------|-----------|-------|------|------------|
| S13       | 35.98     | 3.51  | 54.40| hERG inhibition |
| S18       | 37.25     | 4.18  | 45.17| hERG inhibition |
| S19       | 39.09     | 4.62  | 45.17| hERG inhibition |
| S20       | 45.09     | 4.89  | 45.17| hERG inhibition |
| S21       | 39.45     | 2.83  | 71.19| hERG inhibition, Methaemoglobinemia and Skin sensitisation |
| S22       | 39.39     | 2.90  | 74.27| hERG inhibition and Methaemoglobinemia |
| S23       | 39.58     | 3.36  | 65.40| hERG inhibition |
| S24       | 36.79     | 3.60  | 90.99| hERG inhibition and Carcinogenicity |
| S25       | 38.53     | 3.52  | 68.96| hERG inhibition |
| S26       | 37.12     | 2.50  | 79.31| hERG inhibition |
| S27       | 48.30     | 5.33  | 45.17| hERG inhibition |
| S28       | 48.47     | 5.78  | 45.17| hERG inhibition |
| S29       | 42.99     | 5.12  | 45.17| hERG inhibition |
| S30       | 44.82     | 5.98  | 83.10| hERG inhibition |
| S31       | 46.94     | 6.02  | 24.94| hERG inhibition |
| S32       | 47.87     | 6.50  | 62.87| hERG inhibition |
| S33       | 42.28     | 5.33  | 45.17| hERG inhibition |
| S34       | 44.99     | 5.17  | 45.17| hERG inhibition |
| S35       | 45.32     | 5.17  | 45.17| hERG inhibition |
| S36       | 46.81     | 5.94  | 45.17| Carcinogenicity and hERG inhibition |
| S37       | 46.30     | 4.71  | 45.17| hERG inhibition |
| S38       | 45.04     | 4.85  | 45.17| hERG inhibition |
| S39       | 44.00     | 4.26  | 65.40| Carcinogenicity, Chromosome damage, Skin sensitisation and hERG inhibition |
| S40       | 48.71     | 4.41  | 54.40| hERG inhibition |
| S41       | 45.46     | 5.97  | 45.17| hERG inhibition |

*apossibility ‘PLAUSIBLE’ in Derek 2.0.3. doi:10.1371/journal.pone.0059315.t006
information in hand, we finally designed the third series of compounds (S34–S41, third series in Figure 15), focusing on the substituents on the phenyloxyl group of S13. Different halogens, -OH, -OMe and n-propyl were introduced to the phenyloxyl ring. According to the docking results, compound S40, substituted by -OMe, exhibited the highest docked score. The binding pattern to Hsp90 showed that the -OMe inserted into the sub-pocket P2 as we expected (Figure 14D). The CLoPog and PSA of S40 were 4.41 and 54.40, respectively, indicating an acceptable solubility and druggability. However, according to the Derek predication, all of the designed compounds had potential hERG inhibition effect. This may due to the similarity of the scaffold of the designed compounds to the pharmacophoric structure of hERG inhibitors. The problem needs further biological validation. In summary, the binding affinity, physicochemical properties make S40 a proper lead for the design of novel Hsp90 inhibitor.

**Conclusion**

By the means of ligand based drug design, a 3D quantitative pharmacophore model with reliable prediction ability was established in the present study. By using the model, two active compounds in both Hsp90-based level and cell-level level were identified from the virtual screening. Further biological evaluation of S13 revealed that it induced apoptosis while treated with HCT116, MCF-7 and SK-BR-3 cancer cells, which may be through the downregulation of the client proteins of Hsp90. To obtain compounds with improved potency and druggable characters, we designed 24 derivatives of S13 by a fully consideration of their binding affinities, physicochemical properties and toxicities, resulting a more proper lead compound S40. However, during the toxicity prediction we observed the potential hERG inhibitory effects of the series of compounds. The results need to be validated in future by hERG inhibition assay and more careful consideration of the molecular design strategy may help us to avoid the problem. In summary, S40 can serve as a promising lead for further chemical modification and optimization.

**Author Contributions**

Conceived and designed the experiments: QDY HPS JMJ. Performed the experiments: JZ JMJ XL FL XKG MYZ MCL XLJ SLZ. Analyzed the data: HPS SMZ XLJ. Contributed reagents/materials/analysis tools: JMJ HPS. Wrote the paper: JMJ HPS.

**References**

1. Young JC, Agahe VR, Siegers K, Hartl FU (2004) Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 5: 781–791.

2. Whitehall L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772.

3. Lianard MG, Ramos HC (2009) Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics. Current Chemical Biology 3: 330–341.

4. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2: 3–24.

5. Pratt WB, Tofl DO (2005) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111–133.

6. Chiosis G, Vilenchik M, Kim J, Solit D (2004) Hsp90: the vulnerable chaperone. Drug Discov Today 9: 861–868.

7. Messaoudi S, Peyrat JB, Brion JD, Alami M (2008) Recent advances in Hsp90 inhibitors as anti-tumor agents. Anticancer Agents Med Chem 8: 761–782.

8. Pratt WB, Morishima Y, Peng HM, Osawa Y (2010) Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) 235: 278–289.

9. Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213–217.

10. Kamal A, Boehm MF, Burrows FJ (2004) Heat shock protein 90 as a molecular target for cancer therapeutic. Nat Rev Cancer 5: 761–772.

11. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, et al. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940–7946.

12. Solit DB, Osumi I, Polesky D, Panagoras KS, Dunai A, et al. (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302–8307.

13. Tse AN, Klimenta DS, Gruen M, Shahi M, Shirikh T, et al. (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 14: 6704–6711.